A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects

Bruton’s tyrosine kinase (BTK) is a target for treatment of hematologic malignancies and autoimmune diseases. TAK‐020 is a highly selective covalent BTK inhibitor that inhibits both B cell receptor and fragment crystallizable receptor signaling. We assessed the safety/tolerability and pharmacokineti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Transl Sci
Main Authors: Esfandiari, Ehsanollah, Chen, Mary, Smithson, Glennda, Blair, Derek, Faessel, Helene, Wagner, John, Mclean, Lachy, Fedyk, Eric R.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2021
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212709/
https://ncbi.nlm.nih.gov/pubmed/33650758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12871
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares